PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

Core Insights - PDS Biotechnology Corporation is advancing its investigational flu vaccine, Infectimune, which has shown promising preclinical immune response data at the IMMUNOLOGY2025™ Annual Meeting [1][2] - The vaccine has demonstrated a significantly greater frequency of multifunctional, influenza-specific CD4 T cells compared to current vaccine approaches, indicating its potential effectiveness [2] - Infectimune-based universal flu vaccines have shown excellent breadth of protective immune response against multiple strains of influenza in preclinical studies [3] Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on transforming immune system responses to target and kill cancers and infectious diseases [1][5] - The company is currently conducting a pivotal clinical trial for its lead program, Versamune HPV, aimed at treating advanced HPV16-positive head and neck squamous cell cancers [5] - PDS Biotech is leveraging collaborations to enhance its research while focusing resources on its immuno-oncology programs [4]